Amid this treatment landscape, glucagon-like peptide-1 receptor (GLP-1R) agonists already established as therapies for metabolic disorders have emerged as potential candidates for addiction treatment, with recent research suggesting they may reduce alcohol consumption in preclinical and clinical studies. This evidence concerns the gene GLP1R and metabolic disease.